Press Releases | November 20, 2025
WASHINGTON, D.C. — Today, the U.S. District Court for the District of Columbia rejected Teva Pharmaceuticals’ challenge to the Medicare Drug Price Negotiation Program — marking the 16th defeat against the industry’s nationwide legal campaign to prevent the law from lowering prices. Teva manufactures Austedo and Austedo XR — used to treat involuntary movements associated with Huntington’s disease and tardive dyskinesia — which are included in the second round of negotiation.
The deadline for the second round of lower negotiated prices to be announced is November 30th.
“Patients have triumphed again with a 16th victory over Big Pharma: this time over Teva Pharmaceuticals, the only corporation that filed after its drug was included in the second round of negotiations,” said P4AD Executive Director Merith Basey. “Despite their expensive legal assault, their unfounded and unimaginative arguments were rejected in court. Americans overwhelmingly support Medicare’s right to negotiate lower drug prices, and the courts continue to affirm that this program is constitutional and here to stay.”
The court dismissed both Teva’s Fifth Amendment argument as well as the company’s attempt to challenge the law’s grouping of multiple products under a single negotiation unit. Austedo and AustedoXR share the same active ingredient and differ only in delivery mechanism, undermining the company’s claim that the drugs should be treated as separate. The ruling reaffirmed the constitutionality of the historic medicare negotiation program, which is supported by more than 80% of Americans.
In January 2026, Medicare negotiation will deliver lower prices for its first round of expensive and widely used drugs, delivering $1.5 billion in savings for 9 million people on Medicare and saving taxpayers $6 billion in the first year alone.
Patients For Affordable Drugs has submitted five amicus briefs on behalf of patients and signed onto seven briefs led by Public Citizen and supported by Protect Our Care, Doctors for America, and Families USA to support the government’s opposition to the lawsuits and amplify the experiences of patients harmed by high drug prices.
###
Patients For Affordable Drugs is the only national patient advocacy organization focused exclusively on policies that lower prescription drug prices. We empower and mobilize patients by amplifying their experiences with high drug prices to hold those in power to account and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4AD does not accept funding from organizations that profit from the development and distribution of drugs. To learn more, visit PatientsForAffordableDrugs.org.